Global Toxoid Vaccines Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Toxoid Vaccines Market Size

• The global toxoid vaccines market size was valued atUSD 6.31 billion in 2024 and is expected to reachUSD 10.24 billion by 2032, at aCAGR of 6.25%during the forecast period
• This growth is driven by factors such as Rising Incidence of toxoid-preventable diseases, and government immunization programs

Toxoid Vaccines Market Analysis

• Toxoid vaccines are inactivated bacterial toxins (toxoids) that stimulate an immune response without causing disease. They are crucial in preventing conditions such as tetanus and diphtheria, especially in pediatric and maternal immunization programs
• The demand for toxoid vaccines is significantly driven by the increasing incidence of vaccine-preventable diseases, particularly in low- and middle-income countries, government-led immunization programs, and growing awareness about preventive healthcare
• North America is expected to dominate the toxoid vaccines market, primarily due to its advanced healthcare infrastructure, high immunization coverage, and strong government funding for vaccine research and public health initiatives. The region currently holds 33.13% of the global market share
• Asia-Pacific is projected to be the fastest-growing region in the toxoid vaccines market during the forecast period, driven by rising birth rates, increasing healthcare investments, and greater awareness of childhood immunization programs
• Tetanus segment is expected to dominate the market with a market share of 63.11% due to the high incidence of tetanus-related complications, particularly in unvaccinated populations and high-risk groups such as new-borns and trauma patients

Report Scope and Toxoid Vaccines Market Segmentation

Toxoid Vaccines Market Trends

“Technological Innovations & Expanded Access in Toxoid Vaccines Market”

• One prominent trend in the toxoid vaccines market is the continuous advancement in vaccine formulation technologies and the expansion of access through global immunization initiatives
• These innovations are improving the stability, efficacy, and safety of toxoid vaccines, making them more accessible and effective, especially in resource-limited settings
  • For instance, the development of combination vaccines such as DTaP (Diphtheria, Tetanus, and Pertussis) allows for fewer injections while maintaining strong immune responses, which enhances patient compliance and simplifies immunization schedules
• These advancements are broadening the reach of immunization programs, particularly in developing countries, enhancing disease prevention, and driving demand for next-generation toxoid vaccines that are easier to administer and distribute

Toxoid Vaccines Market Dynamics

Driver

“Growing Need Due to Rising Prevalence of Vaccine-Preventable Diseases”

• The rising prevalence of vaccine-preventable diseases such as tetanus, diphtheria, and whooping cough (pertussis) is significantly driving the demand for toxoid vaccines
• As the global population ages, the incidence of these diseases continues to rise, particularly in low- and middle-income countries where immunization rates may be suboptimal
• Increasing awareness around preventive healthcare, especially regarding maternal and childhood immunization, is fueling the demand for toxoid vaccines, as they are critical in reducing the burden of these diseases

For instance,

• In 2022, the World Health Organization (WHO) reported that tetanus remains one of the leading causes of maternal and neonatal deaths in many regions, particularly in Sub-Saharan Africa and parts of Asia. Such findings emphasize the need for widespread vaccination efforts to protect against these preventable conditions
• As a result, national immunization programs are incorporating toxoid vaccines more widely, increasing the demand for vaccines and driving market growth

Opportunity

“Advancement in Combination Vaccines for Broader Immunization Coverage”

• The development of combination toxoid vaccines (for instance, DTaP, which includes diphtheria, tetanus, and pertussis vaccines) presents a significant opportunity to expand immunization coverage while simplifying vaccination schedules
• These vaccines help reduce the number of injections needed, leading to better patient compliance, especially in pediatric populations, and cost-effective immunization strategies

For instance,

• In 2023, a study published in The Lancet Infectious Diseases highlighted that combination vaccines, such as DTaP-Hib-IPV (which combines diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and polio vaccines), could significantly reduce the healthcare burden by preventing multiple diseases with a single shot
• The integration of toxoid vaccines in combination shots is expected to increase demand as more countries aim for universal immunization coverage

Restraint/Challenge

“High Cost of Vaccine Development and Distribution”

• The high costs associated with the development, manufacturing, and distribution of toxoid vaccines pose a significant barrier to market expansion, particularly in low-resource settings
• While toxoid vaccines are relatively well-established, the complex production process and stringent cold chain requirements for their distribution increase operational costs, which may limit their availability in underserved regions

For instance,

• In a report published by the Global Vaccine Safety Initiative in 2024, the cost of producing vaccines for tetanus toxoid was identified as a barrier to large-scale vaccination programs in some African nations. Despite efforts from international organizations such as GAVI, the high cost of production can limit the number of doses that can be distributed to populations in need
• As a result, financial constraints on governments and healthcare systems can lead to disparities in vaccine access, affecting overall global immunization rates and limiting the market’s growth potential

Toxoid Vaccines Market Scope

The market is segmented on the basis of type, indication, end user and distribution.

In 2025, the tetanus is projected to dominate the market with a largest share in indication segment

The tetanus segment is expected to dominate the toxoid vaccines market with the largest share of 63.11% in 2025 due to the high incidence of tetanus-related complications, particularly in unvaccinated populations and high-risk groups such as new-borns and trauma patients.

The hospital is expected to account for the largest share during the forecast period in end user

In 2025, the hospital segment is expected to dominate the market with the largest market share of 46.74% as it plays a central role in vaccine administration, including routine immunizations and emergency prophylaxis. Their infrastructure, trained healthcare personnel, and capability to handle both routine and emergency immunizations make them the primary centres for vaccine delivery.​

Toxoid Vaccines Market Regional Analysis

“North America Holds the Largest Share in the Toxoid Vaccines Market”

• In 2024, North America accounted for approximately 33.13% of the global tetanus toxoid vaccine market, driven by advanced healthcare infrastructure, high adoption of cutting-edge medical technologies, and the strong presence of key market players
• U.S. holds a significant share of 79.2%, due to increased demand for high-precision vaccines, rising prevalence of vaccine-preventable diseases such as tetanus, and continuous advancements in vaccine development
• The availability of well-established reimbursement policies and growing investments in research & development by leading pharmaceutical companies further strengthen the market
• In addition, the expansion of vaccination programs, coupled with robust government support, is fueling market growth in North America

“Asia-Pacific is Projected to Register the Highest CAGR in the Toxoid Vaccines Market”

• Asia-Pacific is expected to witness the highest growth rate in the toxoid vaccines Market, driven by rapid expansion in healthcare infrastructure, increasing awareness about vaccine-preventable diseases, and rising vaccination volumes
• Countries such as China, India, and Japan are emerging as key markets due to the growing aging population, which is more susceptible to diseases such as tetanus and diphtheria
• Japan, with its advanced medical technology and increasing number of healthcare professionals, remains a crucial market for vaccine adoption. The large populations in China and India also contribute to growing demand, driven by both government and private sector investments in immunization efforts

Toxoid Vaccines Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Bharat Biotech (India)
• CEVA Logistics (France)
• GSK plc. (U.K.)
• Grifols S.A. (Spain)
• Zoetis Services LLC (U.S.)
• Virbac (France)
• Sanofi (France)
• Merck & Co., Inc. (US)
• EMERGENT (U.S.)
• Integrated BioTherapeutics, Inc. (U.S.)
• Abbott (U.S.)
• Avalon Pharma Private Limited (India)
• HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.  (India)
• Pfizer Inc. (U.S.)
• Astellas Pharma Inc. (U.S.)
• Panacea Biotec (India)
• Bio Farma (Indonesia)
• Biological E Limited (India)

Latest Developments in Global Toxoid Vaccines Market

• In August 2024, Pfizer announced that its toxoid vaccine candidate PF-06425090, developed to prevent Clostridioides difficile infection, did not achieve the desired outcomes in its Phase III CLOVER trial. The vaccine demonstrated an efficacy rate of 31% in reducing infections among adults aged 50 and above; however, the results were not statistically significant, falling short of the study's primary endpoint
• In May 2024, ILiAD Biotechnologies reported that its intranasal pertussis vaccine candidate, BPZE1, showed positive results in a Phase 2b clinical trial. Conducted in children aged 6 to 17 across the UK, Australia, and Costa Rica, the trial assessed the vaccine's immune response and safety, both as a standalone treatment and in combination with the Tdap (Boostrix) vaccine, demonstrating promising immunogenicity and tolerability
• In December 2023, Panacea Biotec announced the launch of EasyFourPol, a fully liquid pentavalent vaccine (wP-IPV) in India. Designed to protect children against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type B infections, the vaccine offers a ready-to-use combination format, eliminating the need for on-site preparation by healthcare workers and enhancing the efficiency of immunization programs
• In January 2024, the National Pharmaceutical Pricing Authority (NPPA) granted an extension to the Serum Institute of India (SII), allowing the continued manufacturing of two tetanus toxoid formulations until December 31, 2024. This decision came after a request from SII to discontinue the products, ensuring the availability of these essential vaccines for public health use 

SKU-46280